MyFinsight
Home
Blog
About
Back
Cash Flow
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)
source: myfinsight.com
Net increase
(decrease) in cash and cash...
-$5,355K
(75.32%↑ Y/Y)
Accrued expenses and
other current...
$2,968K
(126.99%↑ Y/Y)
Share-based compensation
$822K
(-63.79%↓ Y/Y)
Prepaid expenses and
other current assets
-$654K
(-6.17%↓ Y/Y)
Non-cash lease cost
$227K
(-58.80%↓ Y/Y)
Other receivables
-$19K
(96.96%↑ Y/Y)
Net cash provided by
(used in) operating...
-$5,355K
(75.32%↑ Y/Y)
Canceled cashflow
$4,690K
Net loss
-$9,552K
(38.64%↑ Y/Y)
Operating lease liability
-$431K
(36.80%↑ Y/Y)
Accounts payable
-$62K
(99.05%↑ Y/Y)
Back